May 25, 2021 / 09:00PM GMT
Eliana Rachel Merle - UBS Investment Bank, Research Division - Analyst
I'm Ellie Merle. I'm one of the biotech analysts here at UBS. Thanks so much for joining us at the UBS Healthcare Conference. Very happy to have Neil Kumar, CEO and Founder of BridgeBio here with us today for a fireside chat. And with that, I'll turn it over to Neil.
Questions and Answers:
Eliana Rachel Merle - UBS Investment Bank, Research Division - AnalystMaybe taking a step back, can you sort of frame for us the business model and philosophy of BridgeBio's structure and how this could sort of increase R&D returns? And then kind of high-level, sort of what your key priorities are over the next couple of years?
Neil Kumar - BridgeBio Pharma, Inc. - Co-Founder, CEO & Director
Sure. Well, first of all, thanks so much for having me here. It's great to speak with you. Can you hear me okay, by the way, is it crystal clear to -- okay. Wonderful. So the BridgeBio business model is actually quite simple. It's something that we set up to
Trustpilot
